BioVie CEO: Promising Phase 2 Results for Long COVID and Parkinson’s Disease

BioVie (NASDAQ: BIVI) President and CEO Cuong Do joins Jane King to discuss new clinical trial results for bezisterim, the company’s investigational treatment for neurological conditions. BioVie recently presented findings from its ADDRESS-LC Long COVID trial and SUNRISE-PD Parkinson’s disease trial at the American Neurological Association Annual Meeting, with findings also published in the peer-reviewed Annals of Neurology. Do highlights statistically significant improvements among Long COVID patients with high baseline symptom burdens, including fatigue, post-exertional malaise, and cognitive impairment or brain fog.

The discussion also covers BioVie’s Parkinson’s trial, where the company reported that 25% of bezisterim-treated patients experienced meaningful symptom improvement compared with 4% receiving placebo, alongside findings involving both motor and non-motor symptoms. Do outlines the company’s plans for Phase 3 clinical trials, upcoming FDA discussions, and a potential Long COVID regulatory submission in early 2028 under an accelerated, best-case timeline. These treatments remain investigational, and larger confirmatory studies will be needed to establish their effectiveness.

#BioVie #BIVI #CuongDo #Bezisterim #LongCOVID #ParkinsonsDisease #ClinicalTrials #Phase2 #Phase3 #Biotechnology #BiotechStocks #Neurology #MedicalResearch #FDA #NewToTheStreet